The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and over with metastatic castration-resistant prostate cancer (mCRPC) to participate in a research study. This research study involves three drugs. The investigational drug is called lorigerlimab (also known as MGD019). An investigational drug means the drug is not approved for the use being tested by any government office that controls new drugs, like the US Food and Drug Administration (FDA). The other two drugs are called docetaxel and prednisone.

The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have advanced non-small cell lung cancer (NSCLC) with any PD-L1 expression. As part of this study, you will either be treated with an investigational medication, fianlimab, a LAG-3 inhibitor, in combination with cemiplimab (a PD-1 inhibitor) or cemiplimab alone. Both medications are administered by IV.

The aim of the study is to see how effective the combination of fianlimab and cemiplimab is in treating advanced NSCLC, in comparison with cemiplimab by itself.

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have relapsed/refractory hematologic malignancies. The purpose of this research study is to test the safety of PRT2527 at different dose levels alone or in combination with Zanubrutinib (also known as BFB-3111) to find out what effects, good and/ or bad, PRT2527 alone or PRT2527 taken together with Zanubrutinib has on you and your type of cancer. You will receive PRT2527 alone or in combination with Zanubrutinib.

The UVA Health System Department of Neurology seeks children and adults ages 10 and older with a diagnosis of functional tremor for a research study.

The purpose of the research study is to evaluate how ease of use of a smartphone-based intervention called “Tremor Retrainer” is for patients with functional tremor.

The study involves a one week at-home smartphone-based intervention and 4 visits to UVA lasting 60-90 minutes each. These will occur weekly for 3 weeks and then again 3 months later.

Study-related exams and intervention provided free of change.

The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have advanced non-small cell lung cancer (NSCLC) with tumors expressing PD-L1 =50%. As part of this study, you will either be treated with an investigational combination, a LAG-3 inhibitor, in combination with a PD-1 inhibitor or a PD-1 inhibitor alone. Both medications are administered by IV.

The aim of the study is to see how effective theinvestigational combination is in treating advanced NSCLC, in comparison with PD-1 inhibitor.

The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have ovarian clear cell or ovarian endometrioid cancer, and have an ARID1a mutation.

Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT05226507

The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have either have breast cancer HER2+ Breast Cancer or Triple Negative Breast Cancer (TNBC) which is in an advanced stage and has metastasized to your brain. The purpose of this study is to test any good and bad effects of the study drug called Dendritic cell vaccines (DC1) and pembrolizumab.

The University of Virginia is participating a clinical research study for adults ages 18 and over, who have newly diagnosed ovarian, fallopian tube or peritoneal carcinoma and you are going to be treated with neoadjuvant chemotherapy followed by interval surgery. If you decide to participate in this study, you will be asked to spend about 4-5 months on this study. You will be randomized to either aspirin or a matching placebo but all patients will receive standard chemotherapy.

The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with acute myeloid leukemia or myelodysplasia with no circulating blasts for a research study. In this study, you will get the usual chemotherapy or in some cases, chemotherapy and radiation treatments for a transplant from a partially matched unrelated volunteer donor. You also will get medicines after transplant to help prevent graft versus host disease, one of the immune system complications after transplant.

The University of Virginia is participating in a clinical research study sponsored by the National Cancer Institute for adults ages 18 and over, who have a solid tumor that has advanced or progressed after treatment with a drug called a PARP inhibitor and your tumor may have abnormalities or changes in the system that repairs damage to your DNA. The purpose of this study is to test the side effects of combining two drugs, called ZEN003694 (ZEN-3694) and talazoparib, as treatment for advanced cancer.